The Computational Molecular Design at ZIB group successfully designed a pain killer without side effects. After the pre-clinical trials at Charité, this drug candidate is now ready for clinical trials. The company DoloPharm UG, which searches for venture capital providers to finance these trials, won the 3rd price of the Berlin-Brandenburg Business Plan Wettbewerb 2017 on February 23rd.
